Evidence map›Paper›PMID 40807193›Full record

ReviewJournal of clinical medicine2025

Obstructive Sleep Apnea and Type 2 Diabetes: An Update.

Sandro Gentile, Vincenzo Maria Monda, Giuseppina Guarino, Ersilia Satta, Maria Chiarello, Giuseppe Caccavale, Edi Mattera, Raffaele Marfella, Felice Strollo

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Obstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease.Diabetic medicine : a journal of the British Diabetic Association · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandro GentileDepartment of Precision Medicine, Vanvitelli University of Naples, 80131 Naples, Italy.ORCID 0000-0002-9059-6121
Vincenzo Maria MondaDiabetes Unit ''Santissima Annunziata'' Hospital Cento, 44042 Ferrara, Italy.
Giuseppina GuarinoDepartment of Precision Medicine, Vanvitelli University of Naples, 80131 Naples, Italy.
Ersilia SattaResearch Department, Nefrocenter Research Network, 80059 Torre del Greco, Italy.
Maria ChiarelloResearch Department, Nefrocenter Research Network, 80059 Torre del Greco, Italy.
Giuseppe CaccavaleResearch Department, Nefrocenter Research Network, 80059 Torre del Greco, Italy.
Edi MatteraDepartment of Precision Medicine, Vanvitelli University of Naples, 80131 Naples, Italy.
Raffaele MarfellaDepartment of Advanced Medical and Surgical Sciences (DAMSS), Vanvitelli University of Naples, 80138 Naples, Italy.ORCID 0000-0003-3960-9270
Felice StrolloDepartment of Endocrinology and Metabolic Diseases, IRCCS San Raffaele Pisana, 00163 Rome, Italy.ORCID 0000-0001-8917-5314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obstructive sleep apnea (OSA) syndrome is a severe, debilitating, and pervasive sleep disorder. OSA mainly affects people with obesity, type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia and is strongly associated with cardiovascular complications. Based on the bidirectional relationship between T2DM and OSA, the latter represents a risk factor for the former, and, vice versa, people with T2DM have a high risk of OSA. Mechanical and hormonal factors, inflammatory mediators, and a dysregulated autonomic nervous system contribute to the mechanisms underlying the disease. Treatment of OSA is necessary even if the available remedies are not always effective. In addition to traditional treatments, including lifestyle adaptations and bariatric surgery, CPAP equipment, i.e., a breathing device ensuring continuous positive pressure to keep the airways open during sleep, represents the most common treatment tool. More recently, pharmacological research has paved the way to newer seemingly effective therapeutic strategies involving, in particular, two hypoglycemic agent classes, i.e., sodium-glucose co-transporter 2 inhibitors (SGLT2-is) and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-ras). This narrative review provides an update on all of the above.

Indexed as

cardiovascular riskobesityobstructive sleep apneasleep disorderstype 2 diabetes

Identifiers

PMID40807193
PMCPMC12347911

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.